Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study.

Evan Y Yu,William R Berry,Howard Gurney,Margitta Retz,Henry J Conter,Brigitte Laguerre,Peter C C Fong,Cristiano Ferrario,Tilman Todenhöfer,Gwenaelle Gravis,Josep M Piulats,Urban Emmenegger,Neal D Shore,Emanuela Romano,Loic Mourey,Xin Tong Li,Christian H Poehlein,Charles Schloss,Leonard J Appleman, Johann S de Bono

European urology oncology（2023）

引用 0|浏览14

暂无评分

摘要

Pembrolizumab plus enzalutamide showed limited antitumor activity and manageable safety in patients with metastatic castration-resistant prostate cancer. The KEYNOTE-365 trial is registered on ClinicalTrials.gov as NCT02861573.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要